L26/O-185 Underrecognized genome-wide uniparental disomy and triploidy in human blastocysts revealed by a concurrent preimplantation genetic testing method
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Choy Kwong Wai.
Abstract (Originalsprache)
Concurrent preimplantation genetic testing (PGT) enhances embryo selection by simultaneously detecting monogenic disorders (PGT-M) or structural rearrangements (PGT-SR) and aneuploidy (PGT-A). However, the detection of triploidy and genome-wide uniparental disomy (gwUPD), two genome- wide abnormalities causative for severe pregnancy outcomes, are not routinely included in conventional PGT platforms and thus remain underrecognized at the preimplantation stage. To address what is the incidence of triploidy and gwUPD in human embryos that are currently undetected by conventional preimplantation genetic testing (PGT), we conducted a three phases: Phase I validated the detection capability of a new sequencing based concurrent PGT (PGT-Plus) on cell lines with previously ascertained genetic abnormalities; Phase II performed retrospective clinical validation on leftover trophectoderm69 biopsy whole-genome amplification (WGA) samples, including 65 for PGT-M, 67 for PGT-70 SR, and 130 for PGT-A received during January 2019 and July 2023; Phase III was prospective implementation of PGT-Plus under a diagnostic setting on 529 blastocysts received from August 2023 to June 2024. Additionally, a cohort consisting of 258 embryo transfers,73 previously ascertained as euploid by conventional PGT-A methods but associated with unfavourable outcomes, were retested by PGT-Plus which identified previously undetected cases of gwUPD or triploidy. Triploidy and gwUPD were detected in 0.8% (8/105) and 1.34% of blastocysts, respectively. Notably, 3.5% (9/258) of the embryo transfers, initially classified as “euploid” but associated with unfavourable outcomes, would have otherwise been prevented if triploidy and gwUPD had been detected. This newly established PGT-Plus approach additionally detected gwUPD and triploidy in preimplantation embryos. It explained another 3.5% of “euploid” transfer failures. Detection of these anomalies at the preimplantation level could lower the risk of hydatidiform mole, miscarriages, and pregnancy-related complications thereby improving overall reproductive outcomes.
Zitieren
APA
Wai, R. C. K. (2026). L26/O-185 Underrecognized genome-wide uniparental disomy and triploidy in human blastocysts revealed by a concurrent preimplantation genetic testing method. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.183
Vancouver
Wai RCK. L26/O-185 Underrecognized genome-wide uniparental disomy and triploidy in human blastocysts revealed by a concurrent preimplantation genetic testing method. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.183
BibTeX
@article{Wai2026,
author = {Wai, R. Choy Kwong},
title = {L26/O-185 Underrecognized genome-wide uniparental disomy and triploidy in human blastocysts revealed by a concurrent preimplantation genetic testing method},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.183}
}
EUVIMED